iShares Biotechnology ETF
IBB
- $160.41
- 4.85
- 2.94%
iShares Biotechnology ETF IBB Strategy
The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector.
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
The investment objective & strategy is a summary of the investment's principal strategy as written in the prospectus. This information is pulled from the most recent product disclosure document.
ETFs News & Analysis
etfs
Why we’re neutral on this popular Aussie ETF
How index construction rules create a suboptimal portfolio.
etfs
Why ETFs win the tax battle over managed funds
These four structural advantages make ETFs a powerful tool for reducing tax drag.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,712.80 | 44.30 | 0.51% |
| CAC 40 | 7,701.95 | 67.36 | -0.87% |
| DAX 40 | 22,300.75 | 312.22 | -1.38% |
| Dow JONES (US) | 45,166.64 | 793.47 | -1.73% |
| FTSE 100 | 9,967.35 | 4.82 | -0.05% |
| HKSE | 24,951.88 | 95.45 | 0.38% |
| NASDAQ | 20,948.36 | 459.72 | -2.15% |
| Nikkei 225 | 53,373.07 | 230.58 | -0.43% |
| NZX 50 Index | 12,935.39 | 41.60 | -0.32% |
| S&P 500 | 6,368.85 | 108.31 | -1.67% |
| S&P/ASX 200 | 8,516.30 | 44.70 | 0.53% |
| SSE Composite Index | 3,913.72 | 24.64 | 0.63% |